These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34237810)

  • 1. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    Eklund M; Jäderling F; Discacciati A; Bergman M; Annerstedt M; Aly M; Glaessgen A; Carlsson S; Grönberg H; Nordström T;
    N Engl J Med; 2021 Sep; 385(10):908-920. PubMed ID: 34237810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker vs MRI-Enhanced Strategies for Prostate Cancer Screening: The STHLM3-MRI Randomized Clinical Trial.
    Björnebo L; Discacciati A; Falagario U; Vigneswaran HT; Jäderling F; Grönberg H; Eklund M; Nordström T; Lantz A
    JAMA Netw Open; 2024 Apr; 7(4):e247131. PubMed ID: 38648061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results after Four Years of Screening for Prostate Cancer with PSA and MRI.
    Hugosson J; Godtman RA; Wallstrom J; Axcrona U; Bergh A; Egevad L; Geterud K; Khatami A; Socratous A; Spyratou V; Svensson L; Stranne J; Månsson M; Hellstrom M
    N Engl J Med; 2024 Sep; 391(12):1083-1095. PubMed ID: 39321360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
    Kasivisvanathan V; Rannikko AS; Borghi M; Panebianco V; Mynderse LA; Vaarala MH; Briganti A; Budäus L; Hellawell G; Hindley RG; Roobol MJ; Eggener S; Ghei M; Villers A; Bladou F; Villeirs GM; Virdi J; Boxler S; Robert G; Singh PB; Venderink W; Hadaschik BA; Ruffion A; Hu JC; Margolis D; Crouzet S; Klotz L; Taneja SS; Pinto P; Gill I; Allen C; Giganti F; Freeman A; Morris S; Punwani S; Williams NR; Brew-Graves C; Deeks J; Takwoingi Y; Emberton M; Moore CM;
    N Engl J Med; 2018 May; 378(19):1767-1777. PubMed ID: 29552975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated Prostate Cancer Screening Using Prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
    Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
    JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    Hugosson J; Månsson M; Wallström J; Axcrona U; Carlsson SV; Egevad L; Geterud K; Khatami A; Kohestani K; Pihl CG; Socratous A; Stranne J; Godtman RA; Hellström M;
    N Engl J Med; 2022 Dec; 387(23):2126-2137. PubMed ID: 36477032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
    Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
    JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results from the PRIMA Trial: Comparison of the STHLM3 Test and Prostate-specific Antigen in General Practice for Detection of Prostate Cancer in a Biopsy-naïve Population.
    Fredsøe J; Sandahl M; Vedsted P; Jensen JB; Ulhøi BP; Borre M; Sørensen KD; Pedersen BG;
    Eur Urol Oncol; 2023 Oct; 6(5):484-492. PubMed ID: 37537016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
    Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
    JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.
    Ahdoot M; Wilbur AR; Reese SE; Lebastchi AH; Mehralivand S; Gomella PT; Bloom J; Gurram S; Siddiqui M; Pinsky P; Parnes H; Linehan WM; Merino M; Choyke PL; Shih JH; Turkbey B; Wood BJ; Pinto PA
    N Engl J Med; 2020 Mar; 382(10):917-928. PubMed ID: 32130814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
    Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
    Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
    Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
    Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of systematic and combined biopsy for the detection of prostate cancer.
    Huang JL; Huang D; Chun TT; Yao C; Zhan YL; Ruan XH; Lai TC; Tsang CF; Pang KH; Ng AT; Xu DF; Ho BS; Na R
    Asian J Androl; 2024 Sep; 26(5):517-521. PubMed ID: 38748865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL.
    Lee DH; Nam JK; Park SW; Lee SS; Han JY; Lee SD; Lee JW; Chung MK
    Yonsei Med J; 2016 May; 57(3):565-71. PubMed ID: 26996553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
    Shakir NA; George AK; Siddiqui MM; Rothwax JT; Rais-Bahrami S; Stamatakis L; Su D; Okoro C; Raskolnikov D; Walton-Diaz A; Simon R; Turkbey B; Choyke PL; Merino MJ; Wood BJ; Pinto PA
    J Urol; 2014 Dec; 192(6):1642-8. PubMed ID: 25117476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.